These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19369961)

  • 1. CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.
    Takeshita A; Yamakage N; Shinjo K; Ono T; Hirano I; Nakamura S; Shigeno K; Tobita T; Maekawa M; Kiyoi H; Naoe T; Ohnishi K; Sugimoto Y; Ohno R
    Leukemia; 2009 Jul; 23(7):1329-36. PubMed ID: 19369961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
    DiJoseph JF; Dougher MM; Kalyandrug LB; Armellino DC; Boghaert ER; Hamann PR; Moran JK; Damle NK
    Clin Cancer Res; 2006 Jan; 12(1):242-9. PubMed ID: 16397048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia.
    Dijoseph JF; Dougher MM; Armellino DC; Evans DY; Damle NK
    Leukemia; 2007 Nov; 21(11):2240-5. PubMed ID: 17657218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.
    Takeshita A; Shinjo K; Yamakage N; Ono T; Hirano I; Matsui H; Shigeno K; Nakamura S; Tobita T; Maekawa M; Ohnishi K; Sugimoto Y; Kiyoi H; Naoe T; Ohno R
    Br J Haematol; 2009 Jun; 146(1):34-43. PubMed ID: 19388933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.
    de Vries JF; Zwaan CM; De Bie M; Voerman JS; den Boer ML; van Dongen JJ; van der Velden VH
    Leukemia; 2012 Feb; 26(2):255-64. PubMed ID: 21869836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.
    Carnahan J; Stein R; Qu Z; Hess K; Cesano A; Hansen HJ; Goldenberg DM
    Mol Immunol; 2007 Feb; 44(6):1331-41. PubMed ID: 16814387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
    Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
    Shor B; Gerber HP; Sapra P
    Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
    Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ
    Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
    Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
    DiJoseph JF; Armellino DC; Boghaert ER; Khandke K; Dougher MM; Sridharan L; Kunz A; Hamann PR; Gorovits B; Udata C; Moran JK; Popplewell AG; Stephens S; Frost P; Damle NK
    Blood; 2004 Mar; 103(5):1807-14. PubMed ID: 14615373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
    Golay J; Manganini M; Facchinetti V; Gramigna R; Broady R; Borleri G; Rambaldi A; Introna M
    Haematologica; 2003 Sep; 88(9):1002-12. PubMed ID: 12969808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
    Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
    van Meerten T; van Rijn RS; Hol S; Hagenbeek A; Ebeling SB
    Clin Cancer Res; 2006 Jul; 12(13):4027-35. PubMed ID: 16818702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines.
    Flieger D; Renoth S; Beier I; Sauerbruch T; Schmidt-Wolf I
    Cell Immunol; 2000 Aug; 204(1):55-63. PubMed ID: 11006018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
    J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.
    Li B; Shi S; Qian W; Zhao L; Zhang D; Hou S; Zheng L; Dai J; Zhao J; Wang H; Guo Y
    Cancer Res; 2008 Apr; 68(7):2400-8. PubMed ID: 18381448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.